Trial Profile

A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axatilimab (Primary) ; Corticosteroids (Primary) ; Methylprednisolone (Primary) ; Prednisone (Primary) ; Ruxolitinib (Primary)
Indications Graft-versus-host disease
Focus Therapeutic Use
Sponsors Incyte Corporation

22 May 2026 Status changed from recruiting to active, no longer recruiting.
12 May 2026 According to an Incyte Corporation media release, data from this study will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden.
30 Apr 2026 According to a Syndax Pharmaceuticals media release, topline data is now anticipated in the fourth quarter of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com